Analysts Offer Predictions for AC Immune FY2026 Earnings

AC Immune (NASDAQ:ACIU) – HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of AC Immune in a research note issued on Friday, August 7th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.60) per share for the year, up from their previous estimate of ($0.84). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for AC Immune’s current full-year earnings is ($0.84) per share.

A number of other equities analysts have also recently issued reports on the stock. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research note on Wednesday, August 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of AC Immune in a research report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.50.

AC Immune Stock Down 3.4%

Shares of NASDAQ:ACIU opened at $2.28 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.93 and a quick ratio of 1.02. The stock has a market cap of $232.04 million, a price-to-earnings ratio of -4.22 and a beta of 1.59. The company has a 50 day moving average of $2.36 and a 200-day moving average of $2.75. AC Immune has a one year low of $2.03 and a one year high of $4.00.

AC Immune (NASDAQ:ACIU) last released its earnings results on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. The company had revenue of $18.67 million for the quarter, compared to the consensus estimate of $9.59 million. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%.

Insider Buying and Selling at AC Immune

In other news, CEO Andrea Pfeifer sold 10,000 shares of the business’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $2.79, for a total value of $27,900.00. Following the completion of the transaction, the chief executive officer owned 3,820,288 shares of the company’s stock, valued at $10,658,603.52. The trade was a 0.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. increased its holdings in shares of AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after acquiring an additional 5,920 shares in the last quarter. EFG International AG bought a new position in shares of AC Immune during the 4th quarter valued at about $41,000. Private Advisor Group LLC acquired a new position in shares of AC Immune in the 3rd quarter valued at approximately $48,000. Susquehanna International Group LLP acquired a new position in shares of AC Immune in the 3rd quarter valued at approximately $63,000. Finally, Sei Investments Co. bought a new stake in AC Immune during the 2nd quarter worth approximately $51,000. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.